Tumor Biology

, Volume 32, Issue 1, pp 13–22

Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies

  • Rafael Molina
  • Elias Alvarez
  • Angeles Aniel-Quiroga
  • Maria Borque
  • Belen Candás
  • Antonio Leon
  • Rafael M. Poyatos
  • Montserrat Gelabert
Research Article

Abstract

CgA is a tumor marker in NET's (neuroendocrine tumors) but different ranges of sensitivity and specificity according to the commercial assay kits used have been reported. Our aim was to compare three commercial available assay kits that use three different methodologies (IRMA, RIA and ELISA) to determine CgA, in a clinical setting: 52 healthy people, 98 patients with benign diseases, 94 patients with non-NET´s malignancies, 20 SCLC and in 79 patients with NET's. Results: Using a cut-off with a 100% specificity in healthy people (6 nmol/L, 60 ng/ml, and 90 ng/ml, for RIA, ELISA and IRMA, respectively), abnormal serum concentrations of CgA were found in a high proportion of patients with renal failure (76.7% ,86,7% and 93.3% with ELISA; IRMA and RIA, respectively) other benign diseases (excluding patients with creatinine concentrations > 1.5 mg/dl)(40,3%, 50% and 53,2% with ELISA, IRMA and RIA, respectively) or in patients with non-NET´s malignancies (excluding SCLC and patients with renal failure) (59,8% ELISA, 55,4%% IRMA, 37% RIA). The highest CgA sensitivity in SCLC was obtained with ELISA (100%) and in NET´s with ELISA (83.3%) and IRMA (80.3%) (RIA 65.2%). ROC curves comparing healthy people and NET´s or NET´s- benigns showed a significantly higher area under the curve (AUC) with ELISA (0.964 and 0.774), or IRMA (0.955 and 0.785), and smaller with RIA (0,806 and 0.691). Conclusions: CgA is not a specific tumormarker and abnormal concentrations may be found in non-NET´s. The higher AUC, sensitivity and specificity obtained with the ELISA and IRMA indicates that these are the best techniques to determine CgA.

Keywords

Cromogranin A Neuroendocrine tumors Tumor markers Method comparison False positive 

References

  1. 1.
    McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994;81:1007–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22:517–30.PubMedGoogle Scholar
  3. 3.
    Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1:238–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Oberg N, Stridsberg M. Neuroendocrine tumors. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers: physiology, pathobiology, technology and clinical applications. Washington: American Association for Clinical Chemistry Press; 2002. p. 339–50.Google Scholar
  6. 6.
    Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Bashir S, Gibril F, Ojeaburu JV, Asgharian B, Entsuah LK, Ferraro G, et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther. 2002;16:1367–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol. 2003;14:1135–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Eriksson B, Arnberg H, Lindgren PG, Lorelius LE, Magnusson A, Lundqvist G, et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med. 1990;228:103–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62 Suppl 1:33–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1999;84:2712–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60:644–52 (Oxf).CrossRefGoogle Scholar
  14. 14.
    Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S69–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13:55–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32:198–202.CrossRefPubMedGoogle Scholar
  19. 19.
    Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab. 1994;78:1139–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23:967–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol. 2008;43:20–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150:299–303.CrossRefPubMedGoogle Scholar
  23. 23.
    Hirschowitz BI, Worthington J, Mohnen J, Haber M. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther. 2007;26:869–78.CrossRefPubMedGoogle Scholar
  24. 24.
    O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem. 1989;35:1631–7.PubMedGoogle Scholar
  25. 25.
    Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol. 2005;152:443–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999;13:145–53.CrossRefPubMedGoogle Scholar
  27. 27.
    Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, et al. Chromogranin A in human hypertension. Influence Heredity Hypertens. 1995;26:213–20.Google Scholar
  28. 28.
    Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Houben P, Lundqvist G, Biedmond I, Jonkers D, Stockbrugger R. 24 hour intragastric ph, basal and meal-stimulated serum gastrin and plasma chromogranin A after short term acid inhibition. Gastroenterology. 1997;112 A 152.Google Scholar
  30. 30.
    Portela-Gomes GM, Stridsberg M. Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem. 2001;49:483–90.PubMedGoogle Scholar
  31. 31.
    Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Oberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol. 1993;139:329–37.CrossRefPubMedGoogle Scholar
  32. 32.
    Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14:473–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffie P, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol. 2001;12 Suppl 2:S79–82.CrossRefPubMedGoogle Scholar
  34. 34.
    Schurmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg. 1992;16:697–701.CrossRefPubMedGoogle Scholar
  35. 35.
    Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–49.CrossRefPubMedGoogle Scholar
  36. 36.
    Bernini GP, Moretti A, Ferdeghini M, Ricci S, Letizia C, D'Erasmo E, et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer. 2001;84:636–42.CrossRefPubMedGoogle Scholar
  37. 37.
    Orr DF, Chen T, Johnsen AH, Chalk R, Buchanan KD, Sloan JM, et al. The spectrum of endogenous human chromogranin A-derived peptides identified using a modified proteomic strategy. Proteomics. 2002;2:1586–600.CrossRefPubMedGoogle Scholar
  38. 38.
    Ferrari L, Seregni E, Lucignani G, Bajetta E, Martinetti A, Aliberti G, et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers. 2004;19:295–304.PubMedGoogle Scholar
  39. 39.
    Mountain CF. Staging classification of lung cancer. A critical evaluation. Clin Chest Med. 2002;23:103–21.CrossRefPubMedGoogle Scholar
  40. 40.
    Stahel RA, Ginsberg R, Haveman K, Havemann K, Hirsch FR, Ihde DC, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989;5:119–26.CrossRefGoogle Scholar
  41. 41.
    Petterson F. Annual report on the results of treatment in gynecologic cancer, vol. 20. Stockholm: FIGO ed; 1988.Google Scholar
  42. 42.
    De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristics curves: a non-parametric approach. Biometrics. 1988;44:837–45.CrossRefGoogle Scholar
  43. 43.
    Stephan C, Wesseling S, Schink T, Jung K. Comparison of eight computer programs for receiver-operating characteristics analysis. Cl Chem. 2003;49:433–9.CrossRefGoogle Scholar
  44. 44.
    Fisher JD. New York Heart Association Classification. Arch Intern Med. 1972;129:836.CrossRefPubMedGoogle Scholar
  45. 45.
    Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol. 2001;22:309–39.CrossRefPubMedGoogle Scholar
  46. 46.
    Rozansky DJ, Wu H, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest. 1994;94:2357–68.CrossRefPubMedGoogle Scholar
  47. 47.
    Leon A, Torta M, Dittadi R, degli UE, Ambrosio MR, Delle FG, et al. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. Int J Biol Markers. 2005;20:156–68.PubMedGoogle Scholar
  48. 48.
    Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer. 1999;79:65–71.CrossRefPubMedGoogle Scholar
  49. 49.
    Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol. 2002;13:614–21.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Rafael Molina
    • 1
  • Elias Alvarez
    • 2
  • Angeles Aniel-Quiroga
    • 3
  • Maria Borque
    • 4
  • Belen Candás
    • 5
  • Antonio Leon
    • 6
  • Rafael M. Poyatos
    • 7
  • Montserrat Gelabert
    • 8
  1. 1.Oncobiology Unit, Laboratory of BiochemistryHospital Clinic of BarcelonaBarcelonaSpain
  2. 2.Servicio de Analisis ClínicosHospital Xeral de VigoVigoSpain
  3. 3.Servicio de Analisis ClínicosHospital cruces de BilbaoBaracaldo, BizkaiaSpain
  4. 4.Servicio de Analisis ClínicosHospital Clinico de MadridMadridSpain
  5. 5.Servicio de Analisis ClínicosHospital de BellvitgeHospitalet de Llobregat, BarcelonaSpain
  6. 6.Servicio de Analisis ClínicosHospital Virgen del RocioSevillaSpain
  7. 7.Servicio de Analisis ClínicosHospital Virgen de las Nieves de GranadaGranadaSpain
  8. 8.Departamento de OncologiaNovartisBarcelonaSpain

Personalised recommendations